Press releases
- Calliditas Q1 report, January - March 2024
- In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
- Invitation to the presentation of Calliditas´s interim report January - March 2024
- Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
- Notice of annual general meeting of Calliditas Therapeutics AB (publ)
- Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
- Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
- Calliditas Therapeutics' 2023 Annual Report Published
- Calliditas Announces Positive NefIgArd Open Label Extension Results
- Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
More ▼
Key statistics
As of last trade Calliditas Therapeutics AB (LC8:MUN) traded at 10.35, -18.31% below its 52-week high of 12.67, set on Dec 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.35 |
---|---|
High | 10.35 |
Low | 10.35 |
Bid | 10.73 |
Offer | 10.84 |
Previous close | 10.00 |
Average volume | 216.67 |
---|---|
Shares outstanding | 59.58m |
Free float | 49.57m |
P/E (TTM) | -- |
Market cap | 7.28bn SEK |
EPS (TTM) | -9.78 SEK |
Data delayed at least 15 minutes, as of May 24 2024 07:04 BST.
More ▼